Keith Regnante Biography and Net Worth

CFO of Keros Therapeutics

Keith Regnante has served as our Chief Financial Officer since February 2020. Prior to joining us, Mr. Regnante served as Chief Financial Officer at Wave Life Sciences and was Vice President of Finance at Shire, where he was on the Financial Leadership Team and the R&D Leadership Team. Previously he held multiple finance positions at Biogen dating back to 1999, including Senior Director of Corporate Finance and Senior Director of Worldwide R&D Finance. Prior to these roles, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.

How old is Keith Regnante?: Mr. Regnante is currently 54 years old. There are 2 older executives and no younger executives at Keros Therapeutics. The oldest executive at Keros Therapeutics is Dr. Jasbir S. Seehra Ph.D., President, CEO & Director, who is 68 years old. Learn More on Keith Regnante's age.
How do I contact Keith Regnante?: The corporate mailing address for Mr. Regnante and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected]. Learn More on Keith Regnante's contact information.
Has Keith Regnante been buying or selling shares of Keros Therapeutics?: Keith Regnante has not been actively trading shares of Keros Therapeutics within the last three months. Most recently, Keith Regnante sold 20,000 shares of the business's stock in a transaction on Thursday, June 8th. The shares were sold at an average price of $47.79, for a transaction totalling $955,800.00. Learn More on Keith Regnante's trading history.
Who are Keros Therapeutics' active insiders?: Keros Therapeutics' insider roster includes Carl Gordon (Director), Carl Gordon (Director), Julius Knowles (Director), Jennifer Lachey (Insider), and Keith Regnante (CFO). Learn More on Keros Therapeutics' active insiders.
Are insiders buying or selling shares of Keros Therapeutics?: During the last year, Keros Therapeutics insiders bought shares 1 times. They purchased a total of 934,258 shares worth more than $9,464,033.54. During the last year, insiders at the sold shares 2 times. They sold a total of 10,176,595 shares worth more than $180,634,561.25. The most recent insider tranaction occured on October, 15th when Major Shareholder Adar1 Capital Management, Llc sold 5,389,264 shares worth more than $95,659,436.00. Insiders at Keros Therapeutics own 20.6% of the company. Learn More about insider trades at Keros Therapeutics.
Information on this page was last updated on 10/15/2025.

Keith Regnante Insider Trading History at Keros Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/8/2023	Sell	20,000	$47.79	$955,800.00

Keith Regnante Buying and Selling Activity at Keros Therapeutics

Keros Therapeutics Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $20.27

$17.95

$20.35

50 Day Range

MA: $16.17

$13.74

$20.27

2 Week Range

Now: $20.27

$9.12

$72.37

Volume

1,191,180 shs

Average Volume

1,292,321 shs

Market Capitalization

$617.63 million

P/E Ratio

13.16

Dividend Yield

N/A

Beta

0.89